Immune modulation mediated by extracellular vesicles of intestinal organoids is disrupted by opioids

Yue Zhang¹, Yan Yan¹, Jingjing Meng¹, Mohit Girotra², Sundaram Ramakrishnan¹ and Sabita Roy*¹

Extracellular vesicles (EVs) are effective mediators of intercellular communications between enterocytes and immune cells. The current study showed that EVs isolated from mouse and human intestinal organoids modulated inflammatory responses of various immune cells including mouse bone-marrow derived-macrophages, dendritic cells, microglia cells, and human monocytes. EVs suppressed LPS-elicited cytokine production in these cells while morphine abolished EVs’ immune modulatory effects. Microarray analysis showed that various microRNAs, especially Let-7, contributed to EV-mediated immune modulation. Using murine models, we showed that injection of EVs derived from intestinal organoids reduced endotoxin-induced systemic inflammation and alleviated the symptoms of DSS-induced colitis. EVs derived from morphine-treated organoids failed to suppress the immune response in both these models. Our study suggests that EVs derived from intestinal crypt cells play crucial roles in maintaining host homeostasis and opioid use is a risk factor for exacerbating inflammation in patients with inflammatory diseases such as sepsis and colitis.

Mucosal Immunology (2021) 14:887–898; https://doi.org/10.1038/s41385-021-00392-9

INTRODUCTION
The gastrointestinal tract is continuously exposed to food antigens and microbes. To maintain host homeostasis, the enterocytes have to communicate with the immune cells to keep the balances between tolerance to commensal bacteria and the ability to initiate efficient defense responses to harmful pathogens. The disturbance of intestinal homeostasis results in autoimmune diseases such as inflammatory bowel disease (IBD), which is characterized by chronic and exacerbated inflammation in the gut.

Recently, it has been revealed that extracellular vesicles (EVs), the 30–100 nm membranous vehicles, are able to mediate the interactions between intestinal epithelial cells and the immune system.¹ EVs isolated from different tissue sources have been shown to generate multiple effects on the immune system. For instance, dendritic cell-derived EVs were shown to indirectly activate CD4 positive T cells,² while intestinal epithelial cell-derived EVs play an important role in the induction of Treg cells.³ Also, tumor-derived EVs have been shown to induce various immunomodulatory effects.⁴,⁵ Although the intestinal epithelial cells have been shown to be able to release EVs,⁶ very few studies have been performed to understand whether the intestinal epithelium-derived EVs are able to modulate cytokine production in different types of immune cells and the physiological consequences of such modulation. In order to explore the role of EVs in inflammation, this study isolated EVs released by intestinal organoids and determined the inflammatory responses of different immune cells in the presence of these EVs. Intestinal organoid cultures are three-dimensional in vitro models that incorporate most of the physiologically relevant features of the in vivo intestinal tissue.

Our lab has previously reported that chronic morphine treatment could manipulate gut immune environment. More specifically, with regards to sepsis, this manipulation resulted in both persistent inflammation and higher mortality.⁶,⁷ To understand whether opioid treatment can interfere with the immune modulatory function of EVs, we characterized the effects of organoid-derived EVs on the responses of immune cells to endotoxin stimulation and investigated the role of morphine treatment in this process. To study whether the effects of EVs on immune cells were altered by morphine treatment, we utilized saline- or morphine-pretreated mouse or human organoids as the donors of EVs and respective mouse bone-marrow derived-macrophages, dendritic cells, microglia cells, and human monocytes as the recipients.

We further identified the specific compositions of EVs secreted by saline- or morphine-treated organoids and demonstrated that multiple microRNAs especially Let7 were packaged in EVs. These microRNAs play crucial roles in maintaining normal immune function. Our results also suggested that Let7 delivered by EVs acted as a key molecular regulator controlling inflammation, which was compromised by use of opioids.

RESULTS
Intestinal organoid-derived EVs inhibits endotoxin-induced inflammatory cytokines in bone marrow-derived dendritic cells (BMDC)

Initially we show that intestinal organoid maintained in conditioned medium with or without morphine (1 μM) continuously secrete EVs. Multiple ultracentrifugation or an ExoQuick Kit from

¹Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL, USA and ²Division of Gastroenterology, Miller School of Medicine, University of Miami, Miami, FL, USA
Correspondence: Sabita Roy (sabita.roy@miami.edu)
These authors contributed equally: Yue Zhang, Yan Yan, Jingjing Meng
Received: 31 July 2020 Revised: 2 February 2021 Accepted: 11 February 2021
Published online: 14 April 2021

© The Author(s), under exclusive licence to Society for Mucosal Immunology 2021
System Biosciences was used to purify EVs from the supernatants of saline- or morphine-treated organoids. The EVs harvested from the supernatants were visualized using transmission electron microscopy (TEM). Our data show no significant difference in the shape and particle size distribution between two samples using different purification methods (Supplementary Fig. 1A), so we chose to use ExoQuick Kit for EV purification in the following experiments. Western blot assays revealed that both samples contained high levels of the Exosome-specific protein markers CD63, CD9, and Tsg101, but have relatively low levels of β-actin compared to organoid cell lysate (Supplementary Fig. 1B).

To determine if immune cells can take up exogenous EVs, we labeled organoid-secreted EVs with PKH67 dye (green) and incubated them with either a BMDC or BMM culture for 24 h. Immunofluorescent images confirmed that recipient cells with F-actin (red) expression colocalized with PKH67-labeled EVs (Supplementary Fig. 2).

Next, to study the role of EVs in mediating immune responses in different cell types, we used the mouse intestinal organoid as an EV donor. When the recipient cells were BMDCs, our results showed that the treatment of EVs alone did not make any significant differences in the expression of pro-inflammatory cytokines. However, in the condition of LPS stimulation, EVs derived from saline-treated organoids (EV(Org/S)) significantly reduced the mRNA levels of pro-inflammatory cytokines like IL-6, TNFα, and IL-1β. In contrast, EVs derived from morphine-treated organoid (EV(Org/M)) did not significantly reduce the pro-inflammatory response (Fig. 1a–c). In addition, EV(Org/S) increased LPS-induced mRNA of anti-inflammatory cytokines IL-2, IL-10, and IL-25 (Fig. 1d–f), while EV(Org/M) abolished this effect. The protein levels of IL-6 and TNFα were validated using ELISA (Fig. 1g, h).

Under LPS stimulation condition, when BMDC were treated with the EVs that were derived from mouse colonic organoid, both IL-6 (Supplementary Fig. 2A) and TNFα (Supplementary Fig. 2B) protein levels were dramatically reduced in the supernatant. Cytokine reduction in the supernatant, however, was significantly negated by the EVs isolated from morphine-treated colonic organoid. Our results indicate that both small intestinal and colonic organoids are able to secrete EVs that can modulate cytokine expression in immune cells and this effect was negated by morphine treatment.

Bone marrow-derived macrophages (BMMs) and microglia exhibited similar responses to endotoxin stimulation after uptake of intestinal organoid-derived EVs.

When the recipient cells were BMMs, EVs’ modulation of inflammatory response to LPS could be seen at both mRNA and protein levels (Fig. 2). After LPS treatment, EV(Org/S) significantly reduced mRNA level of pro-inflammatory cytokines IL-6, TNFα, and IL-1β were observed, while these effects were abolished with EV (Org/M) from morphine-treated organoids. (Fig. 2a–c). Interestingly, EV(Org/S), but not EV(Org/M), increased mRNA levels of anti-inflammatory cytokines such as IL-2, IL-10, and IL-25 induced by LPS (Fig. 2d–f). These effects were further validated using protein analysis. EV(Org/S) decreased the protein levels of IL-6 and TNFα in the supernatant of LPS activated BMM. Protein levels of these cytokines were not observed with EVs derived from morphine-treated organoid (Fig. 2g, h).

We next tested the impact of EVs on microglia as the recipient cells. Our results showed similar effects with that observed with BMM following LPS stimulation. EV(Org/S) significantly reduced the mRNA levels of pro-inflammatory cytokines TNFα, IL-6 and IL-1β, while increasing the levels of anti-inflammatory cytokines IL-10. In contrast EV(Org/M) significantly inhibited these effects (Supplementary Fig. 3A–F). EV(Org/S) also decreased the IL-6 and TNFα protein levels in the supernatant of SIM-A9 microglial cells after LPS incubation, as shown by ELISA (Supplementary Fig. 3G, H).

EVs derived from human colonic organoids modulated inflammatory cytokine expressions in differentiated THP-1 cells. When we used human organoid culture as an EV donor and human macrophages as the recipient, we saw similar results as indicated above (Fig. 3). EV(Org/S) could significantly reduce the mRNA levels of pro-inflammatory cytokines IL-6, TNFα, and IL-1β in THP-1 cells after LPS stimulation, while EV(Org/M) did not have these effects (Fig. 3a–c). EV(Org/S) also significantly decreased the secretion of IL-6 and TNFα proteins in supernatant of differentiated THP-1 after LPS incubation, while EV(Org/M) abolished these effects (Fig. 3d, e).

Taken together, EVs derived from saline-treated organoids could suppress recipient cells’ inflammatory responses to endotoxin stimulation. However, EVs derived from morphine-treated organoids did not have such effects. Next, we investigated the components of EVs in the presence and absence of morphine treatment.

MicroRNA profile in saline- or morphine-treated organoid-derived EVs show significant differences. It has been well established that microRNA could be delivered between cells by EVs, thus mediating cell-to-cell communication.9–12 We isolated the total RNA from EVs derived from saline- or morphine-treated organoid, and performed a real-time PCR based microRNA array assay. The results showed that although there were individual differences between samples within each group, some microRNAs, like miR23a, miR181a, and Let7c, still demonstrated significant differences in expression levels between EV(Org/S) and EV(Org/M). (Fig. 4a). These microRNAs all have predicted target genes related to signaling pathways that were involved in inflammation (Fig. 4b). For example, Let7c-5p potentially targets IL-6 and TLR4; IL-1α is a predicted target of miR181a and miR410, while several microRNAs including miR302d would potentially regulate the expression of IL-25.

We then checked the levels of these individual microRNAs in the EVs that were derived from mouse small intestinal organoids treated with morphine. In the EVs from morphine-treated organoids, as shown in Fig. 4c; Let7c-5p levels were decreased while the levels of miR186, miR181a, and miR302d were increased. These detected changes were consistent with the microRNA array results.

Next, we investigated if these microRNA level changes in EVs were correlated to the microRNA changes in the donor cells. Interestingly, the decrease in Let7c-5p, Let7b, and miR23a levels and the increase in miR186 levels were also observed in the donor intestinal organoid (Fig. 4d). These results indicated that the microRNA profile changes induced by morphine affected the microRNA packaging into the EVs. And the microRNA changes in the EVs interfered with the intercellular communication between the donor organoids and the recipient inflammatory cells.

We also determined the microRNA expression in human organoids and their EVs (Fig. 4e, f). Interestingly, the dramatic decrease of Let7c-5p induced by morphine was consistently observed in mouse and human organoids and the EVs produced by these organoids.

As previously discussed, Let7c-5p has predicted targets of IL-6 and TLR4, with the former as an important cytokine in early immune response and the latter as the receptor specific for LPS. With our previous results demonstrating that, in the presence of EVs derived from intestinal organoids, IL-6 was decreased, we next tested whether the anti-inflammatory effects of EVs were mediated by Let7c-5p.

Effect of EVs on inflammatory cytokine expression was mediated by Let7c-5p: Let7c and other Let7 family microRNA have been shown to directly target IL-6 3′UTR (Fig. 5a) and downregulate IL-6 expression levels.13,14 Here we transected an LNA-enhanced antisense miRNA
inhibitor into BMDC, which efficiently reduced the Let7c-5p levels and inhibited the microRNA's function (Fig. 5b). As shown in Fig. 5c, when the negative control (NC) inhibitor was transfected into BMDC and the transfected BMDC were treated with LPS to simulate inflammatory response, the IL-6 mRNA expression was dramatically induced. And the IL-6 mRNA level was decreased with the treatment of EVs derived from mouse small intestinal organoid. However, when the Let7c-5p inhibitor was present in BMDC cells, the EVs could no longer reduce IL-6 mRNA levels (Fig. 5c). The IL-6 protein levels showed the same trend (Fig. 5d). These results suggested that when Let7c-5p was delivered into BMDC by EVs, it could directly target IL-6 and inhibit IL-6 expression. Additionally, the EV induced changes of TNFα mRNA (Fig. 5e) and protein level (Fig. 5f) were also influenced by the Let7c inhibitor in BMDC, but not as much as IL-6. This study demonstrated that Let7c-5p plays an important role in the anti-inflammatory effect of organoid EVs on recipient BMDC cells.

EVs exhibited anti-inflammatory effects in LPS-induced sepsis model

After we confirmed that EVs derived from saline-treated intestinal organoids could suppress immune responses stimulated by LPS in vitro, we investigated whether this effect could also be seen in vivo. An LPS-induced acute inflammation mouse model (Fig. 6a) was used to measure the pro-inflammatory cytokines in plasma and spleen. The results showed that intravenous injection of saline-treated intestinal organoid-derived EVs could significantly reduce IL-6 (Fig. 6b) and TNFα (Fig. 6c) protein levels in the plasma, but not in the spleen (Fig. 6d, e). Injection of morphine-treated intestinal organoid-derived EVs, however, abolished this effect. These data further support our
conclusion that EVs derived from saline-treated intestinal organoid have an anti-inflammatory effect on the immune system.

EVs treatment resulted in decreased severity in a DSS-colitis model. To further investigate whether EVs also modulate local intestinal inflammation, the DSS-induced colitis model in C57BL/6 mice (Fig. 7a) was used. By adding DSS in the drinking water for 9 days, mice exhibited dramatic weight loss and shortening of the colons (Fig. 7b–d). Using the weight loss (Fig. 7b) and shortening of the colons (Fig. 7c, d) as indicators of the severity of colitis, we observed that intravenous injection of saline-treated intestinal organoid-derived EVs prior to DSS-inducement (ES + DSS) could significantly alleviate the severity of colitis. On the other hand, morphine-treated intestinal organoid-derived EVs (EM + DSS) abolished these effects. Representative H&E-stained sections showed that DSS caused extensive inflammation induced damage on the colon tissue, when compared to both DSS and EM + DSS groups, organoid-derived EVs could ameliorate the extent of the damage (Fig. 7e, f). EVs also inhibited the induction of serum inflammation in DSS-treated mice, as shown by IL-6 ELISA (Fig. 7g). Yet the expression of TNFα was not affected by EV injection. Taken together, these data support our conclusion that saline-treated intestinal organoid-derived EVs have a protective effect on the DSS-induced colitis, by reducing excessive inflammation induced damage in the colon.

Let7c-5p levels in EVs isolated from plasma, small intestine, and large intestine were reduced in DSS/Morphine-treated mice. Our earlier study has shown that morphine could exaggerate DSS-induced mucosal inflammation syndrome. As shown in Fig. 7, the EVs that are derived from intestinal organoid, rather than morphine-treated organoid, could efficiently alleviate colitis. In addition, Let7c-5p was suggested to be an important component in the EVs that mediated the anti-inflammatory effect (Fig. 5). We initially investigated if Let7c-5p levels in the EVs were altered when the mice underwent DSS-induced mucosal inflammation syndrome.
DSS was added to the drinking water for 9 days (Fig. 8a), the body weight of the mice was decreased (Fig. 8b), and their colon lengths were reduced (Fig. 8c). When the mice were injected with Morphine at the same time, the effects were more dramatic with greater weight loss, and more severe colon length shortening (Fig. 8b, c). We isolated the EVs from the plasma, small intestinal tissue as well as large intestinal tissue, and measured the Let7c-5p levels in the EVs. In the DSS-treated mice, Let7c-5p in both the plasma EVs (Fig. 8d) and small intestine EVs (Fig. 8e) were dramatically reduced. In addition, when the mice were treated with Morphine, Let7c-5p levels was significantly and further reduced in EVs derived from both small intestine (Fig. 8e) and large intestine (Fig. 8f).

These findings were consistent with our in vitro data (Fig. 4) showing the morphine treatment would reduce the Let7c-5p levels in both intestinal organoid and its secreted EVs. Since Let7c levels were already dramatically reduced by DSS, the combination of morphine and DSS did not show a synergistic effect. Interestingly, when mice were treated with DSS, neither Let7c nor the U6 microRNAs was detected in the large intestine. It is plausible that the dramatic decrease in EV secretion may be a consequence of significant cellular damage caused by DSS treatment. These studies suggest that the reduced Let7c-5p in the circulating EVs or within the local intestinal environment contribute to DSS triggered-inflammation in the gut. This effect can be further exacerbated by morphine treatment by reducing Let7c-5p levels in the intestine.

**DISCUSSION**

In this study, we demonstrate that the extracellular vehicles (EVs) secreted by crypt cells derived from small and large intestines play an important role in maintaining the intestinal mucosal homeostasis. We provide evidence that specific miRNAs transported by these EVs are used by the immune system to fine-tune immune responses to various exogenous stimulations.

Our results also indicate that EV-mediated immune modulation can be significantly influenced by various factors like opioid exposure. Opioids are commonly prescribed for pain management in patients who are suffering from acute or chronic pain. For example, a population-based analysis indicates that the likelihood of being exposed to an opioid following a diagnosis of IBD was 72% at 10 years post diagnosis.16 Due to their analgesic and sedative activities, opioids are frequently used to treat hospitalized patients.17 Multiple clinical studies show that opioid use is associated with worse outcomes of inflammatory diseases including IBD and sepsis.18–20 However, the mechanistic role of opioid in disease progression still remains poorly understood. Numerous animal studies suggest that opioid treatment can disrupt the tightly balanced tolerance to inflammation, resulting in abnormal inflammatory responses, accelerated disease progression, and poor prognosis. Using the murine model of DSS-induced colitis and spontaneous colitis (IL-10 knockout mice), we recently showed that hydromorphone exacerbated colitis. Hydromorphone treatment enhanced pro-inflammatory cytokine production and subsequent intestinal tissue damage in both mouse models of mucosal inflammation, which was consistent with morphine’s effects observed in the present study.15 Furthermore, we previously showed in two sepsis models, one of which was sepsis induced by LPS and the other was sepsis induced by Cecal-ligation puncture, morphine caused persistent or excessive inflammatory responses.6,7 However, the mechanisms underlying how opioid use disrupts host immune homeostasis is still not clear.
In this study, we provide evidence that opioid treatment can disrupt gut immune homeostasis by inhibiting packaging of miRNA into EVs secreted by intestinal crypt cells. We also identified Let7 as the crucial microRNA in EVs that was able to modulate inflammatory responses of various immune cells. Morphine treatment led to a decrease in EVs' Let7 levels, resulting in abnormal inflammatory responses of bystander immune cells in the intestine.

### Table 1: miRNA changes in saline or morphine pre-treated organoids-derived EV.

| miRNA ID     | Morphine group / saline group | Predicted targets                        |
|--------------|-------------------------------|------------------------------------------|
| mmu-let-7b-5p| Down                          | lgdcc3, TLR7, IL-10, IL-13               |
| mmu-let-5c-5p| Down                          | TLR4, IL-6, IL-13, Mapk6                 |
| mmu-miR-106a-5p| Up                         | IL-25, CD274, Btg3, Irf9                |
| mmu-miR-106b-5p| Up                         | Map3k, Ephr4 A4, TNF21                  |
| mmu-miR-128-3p| Up                           | szrd1, GABA Ar A6                       |
| mmu-miR-15a-5p| Up                           | cyclin D, cyclin E, Akt3, MAPKAP1        |
| mmu-miR-181a-5p| Up                          | smad, IL-1 alpha                        |
| mmu-miR-186-5p| Up                           | CDK12, Tnf1                             |
| mmu-miR-23a-3p| Up                           | C5ar1, CD274, mucin1, I1r1              |
| mmu-miR-294-3p| Up                           | IL-25, Map3k, Cnot6, IRF6               |
| mmu-miR-302d-3p| Up                         | IL-25, IRF9, IFN, Wnt3                 |
| mmu-miR-350-5p| Up                           | CD163, Crb1                             |
| mmu-miR-410-3p| Up                           | IL-1 alpha, IL-12b, Camk2b             |
| mmu-miR-568   | Up                           | Cadm2, Neurod1, Tip1, CD207            |
| mmu-miR-93-3p| Up                           | IL-25, smad5, creb1, Map3k              |

All results are expressed as the mean ± SEM of triplicate measurements in each group, *p < 0.05; **p < 0.01; ***p < 0.001.

**Fig. 4** The microRNA profile in organoid-derived EVs and organoids. 

- **a** Heat map of microRNA microarray expression in EV samples derived from mouse small intestinal organoid that were pretreated with saline (EV(Org/S)) (n = 6) or morphine (EV(Org/M)) (n = 6).
- **b** Various inflammation related genes were predicted with Target-Scan database (http://www.targetscan.org) to be the targets of the microRNAs whose levels were changed in the EV samples shown in (a).
- **c** The change of individual microRNA levels in EV samples derived from mouse small intestinal organoids that were treated with saline or morphine.
- **d** The change of individual microRNA levels in the mouse small intestinal organoids that were treated with saline or morphine.
- **e** The change of individual microRNA levels in EV samples derived from human colonic organoids that were treated with saline or morphine.
- **f** The change of individual microRNA levels in human colonic organoids that were treated with saline or morphine.
Our findings indicate the possible therapeutic implications of EV loaded microRNAs. In physical conditions, EVs secreted by the intestinal crypt cells seems to have a beneficial effect on the LPS-induced sepsis mice and DSS-induced inflammation mice models. For example, Ma et al. found that the exosomes released from mesenchymal stromal cells is reported to possess an immuno-suppressive effect in vitro and exhibit a therapeutic capability in a mouse model of DSS-induced colitis.\textsuperscript{21} In another study, the exosomes derived from granulocytic myeloid-derived suppressor cells were shown to attenuate DSS-induced colitis through inhibiting Th1 cells proliferation and promoting Tregs expansion.\textsuperscript{22} However, the exact contents transferred by EVs that were able to shape the immune system that reside within the intestinal mucosa has not been characterized in these studies.

EVs contain proteins, lipids as well as nucleic acids such as DNA, mRNA, and non-coding RNAs.\textsuperscript{23} EV-mediated transfer of micro-RNAs has been shown to be an important mechanism of genetic exchange between cells.\textsuperscript{1} EVs carrying the micro-RNAs, such as miR181, miR155, and Let7c, function as immune modulators.\textsuperscript{24} Alexander el al. showed that exosome-delivered microRNAs, including miR155 and miR146a, differentially modulate the inflammatory response to endotoxin.\textsuperscript{10} Here, we detected almost one hundred microRNAs in the EVs that were derived from small intestinal organoids (Fig. 4a). In addition, we found that microRNA levels in both the EVs and the donor organoids were changed by morphine treatment (Fig. 4b, c, d), indicating that morphine might exert its gut immune-regulatory effect, at least partially, through modulating the microRNA expression levels in the intestinal crypts. As a result, morphine may impact the cargo of secreted EVs which would transfer these regulatory microRNA molecules to the recipient immune cells. One of these important microRNAs is Let7c-5p. Let7c and other Let7 family microRNA have been shown to directly target IL-6 3′UTR and downregulate IL-6 expression which is involved in inflammatory response.\textsuperscript{13,14} Our study showed that the Let7c-5p levels in the morphine-treated organoid EVs was significantly reduced, and these EVs could no longer inhibit the IL-6 expression in the recipient BMDC. In addition, the presence of the Let7c-5p inhibitor in these BMDC efficiently abolished the anti-inflammatory effect of the naïve organoid EVs (Fig. 5). These results suggest the important role of EVs that contain Let7c-5p in the communication between the gut crypt and the local/distal immune cells. However, we cannot completely exclude the potential roles of other miRNAs in the EVs, such as miR186 and miR23a, both of which also target cytokines or inflammatory molecules (Fig. 4b). Future functional studies regarding these microRNAs or other nucleic acid molecules and proteins in the EVs will give us deeper insight of the EV-mediated intracellular communication, and more importantly will unravel some novel EV-based therapeutic strategy.

The prevalence of EVs in body fluid including plasma, urine, saliva and gut mucus not only supports the hypothesis that EVs exert important functions in physiological and pathological
processes, but also suggests their potential roles as biomarkers, especially under pathological conditions. EV-microRNAs have been tested as biomarkers for cancer diagnosis and prognosis. An elevated serum exosomal miR-21 level was observed in pancreatic adenocarcinoma, while miR17-5p was shown to correlate with cancer stages and a subset of serum exosomal microRNAs was shown to be an early biomarker for AML. In our study of DSS-induced mucosal inflammation mouse model, Let7c-5p levels in the plasma EVs were dramatically decreased (Fig. 8d) when the mice were treated with DSS or morphine, however, decreased the amount of Let7c-5p in the plasma or intestinal EVs, resulting in pathogenic inflammation in the gut. These observations suggested that the level of Let7c-5p in the plasma EVs could be applied as a potential clinical biomarker for IBD due to its ease of access and stability.

Our current study suggests the potential role of intestinal EVs in maintaining the gut immune homeostasis by secreting microRNAs that modulate the inflammatory responses of bystander immune cells. Morphine treatment results in the change of components in the EVs, especially the decrease of Let7, eventually disrupting the homeostasis in the gut and causing more severe inflammation. Our study provides new evidence to support the application of EVs as either a diagnostic tool or a therapeutic approach for controlling inflammatory diseases, such as sepsis and colitis. In addition, our findings also demonstrate the implications of EVs, like exosomes, as useful vectors for mediating microRNA delivery in the development of novel therapeutic strategies.

METHODS

Animals
Eight-week-old C57BL/6J (WT) mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA). Animal maintenance and procedures were conducted according to the Institutional Animal Care and Use Committee policies at the University of Miami.

Mice received intravenous injections of 1 mg (total protein) organoid-derived EVs in PBS. Twenty-four hours later, mice received 500 ng/kg lipopolysaccharide (LPS) by intraperitoneal injection. Fig. 6 Intravenous injection of EVs from saline-treated intestinal organoids reduced the LPS-induced systemic inflammation in mice, while EVs from morphine-treated organoids did not have such effect. a) Experiment timeline. b–e) Measurement of pro-inflammatory cytokines IL-6 and TNF-α in the plasma (b, c) and spleen (d, e) by ELISA. (The results are expressed as the mean ± SEM of measurements from N = 5–12 per group, and each dot represents a measurement from one animal; *p < 0.05; **p < 0.01; ***p < 0.001).
Fig. 7 Intravenous injection of EVs from saline-treated intestinal organoid (ES) alleviated DSS-induced colitis symptoms in mice, while EVs from morphine-treated organoids (EM) did not show these effects. a Experiment timeline. b Measurements of mice body weight in each group. c, d The length of colon in each group showed significant difference by EVs i.v. injection. e Representative images of colon tissue with H&E staining of control and DSS-treated mice (Scale bars, 50 µm). f The histology scores were estimated according to the scoring system for colitis. g, h Measurement of pro-inflammatory cytokines IL-6 and TNFα in the plasma of each group of mice by ELISA. (The results are expressed as the mean ± SEM of measurements from \( N = 6–10 \) animals per group, and each dot represents a measurement from one animal; \(* p < 0.05; ** p < 0.01; *** p < 0.001; \# p < 0.05\).)
p.i. injection. Two hours later, mice were sacrificed and their serum, spleen were processed for cytokine measurement by ELISA. For colitis model, four groups of mice received tail-vein injection of PBS or EVs on day 0, and then three experimental groups of mice received 2.5% dextran sulfate sodium (DSS) in drinking water for 9 days, while control group received normal water. The body weight of each group of animals was recorded every 2 days. On day 10, mice were sacrificed, and intestinal damage was accessed by histological analysis.

Cell culture
CS7BL/6J mice were sacrificed and their femur bones were removed for bone-marrow primary culture. Bone-marrow cells were maintained in complete Iscove modified Dulbecco medium (IMDM; Gibco, Gaithersburg, MD, US), supplemented with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin. BMDCs were generated by 6–7 days of differentiation in complete medium added with 20 ng/ml granulocyte macrophage-colony stimulating factor (GM-CSF), and 10 ng/ml recombinant mouse IL-4 protein (R&D Systems, MN, US). BMDCs were generated by 6–7 days of differentiation in complete medium added with 20 ng/ml mouse macrophage-colony stimulating factor (M-CSF). Fluorescence activated cell-sorting analysis were used to validate these cell types.

The Sim-A9 mouse microglia cell line were purchased from ATCC (https://www.atcc.org/products/all/TIB-3265) and maintained in DMEM/F12 Medium (Gibco, Gaithersburg, MD, US), supplemented with 5% heat-inactivated horse serum, 10% FBS, and 1% penicillin/streptomycin.

The THP-1 human monocyte cell line were purchased from ATCC (https://www.atcc.org/products/all/CRL-2292) and maintained in RPMI-1640 Medium (Gibco, Gaithersburg, MD, US), supplemented with 0.05 mM 2-mercaptoethanol, 10% FBS, and 1% penicillin/streptomycin. These monocytes were differentiated into macrophages by 24 h incubation with 150 nM phorbol 12-myristate 13-acetate (PMA, Sigma, P8139).

Organoid culture
Intestinal organoid cultures were established using the intestinal crypts isolated from the mouse or human samples as previously described. For mouse intestinal organoid culture, the intestines were opened longitudinally and washed with cold phosphate-buffered saline (PBS). The tissue was then cut into 2–4 mm pieces and further washed at least 10 times by pipetting up and down with cold PBS. Tissue fragments were incubated with Gentle Cell Dissociation Reagent (STEMCELL Technologies) for 15 min at room temperature. After removal of the Cell Dissociation Reagent, tissue fragments were washed with PBS to release crypts. Supernatant fractions enriched in crypts were collected, passed through a 70 μm cell strainer, and centrifuged at 300 × g for 5 min. The cell pellet was redissolved with Dulbecco's modified Eagle medium/F12 medium and centrifuged at 200 × g. Crypts were then entrapped in Matrigel (growth factor reduced; BD Bioscience) and cultured using advanced Dulbecco's modified Eagle medium/F12 containing various growth factors in the presence or absence of 1 μM morphine. Human colon samples were obtained from patients undergoing colonoscopy at University of Miami Hospital with written informed consent under an approval of the ethical committee (IRB Number 20160338). Non-inflamed colon samples from two patients were used in this study. Collected tissues were transferred into cold PBS and placed on ice until use. Colon tissues were minced into small pieces. Tissue fragments were processed and cultured using the same protocol as for the mouse organoid culture. The human organoids were grown in conditioned medium produced by a supportive L-WRN cell line as previously described.

Isolation of EVs from culture medium, mouse plasma, small intestine, and large intestine
EVs were recovered from the supernatant of cultured organoids for 72 h. The supernatants were centrifuged at 3000 × g for 10 min to remove cell debris, then purified by filtration on 0.22 μm pore filters, followed by ultracentrifugation at 100,000 × g at 4 °C for 2.5 h.
as described before, or using an ExoQuick isolation kit (System Biosciences, Palo Alto, CA, US) based on the manufacturer’s protocol. In each EV preparation, the concentration of total proteins was quantified by Bradford assay (Bio-Rad, Hercules, CA, US). The size and shape of EVs were visualized with TEM in the University of Miami TEM imaging core as described.

EVs were collected from the plasma using the ExoQuick Plasma Prep with Thrombin kit (System Biosciences, Palo Alto, CA, US) according to the manufacturer’s protocol. Briefly, plasma samples (~200 µl) were pretreated with thrombin. After centrifugation at 10,000 rpm for 5 min, the supernatant was transferred to a fresh tube and treated with ExoQuick precipitation reagent to precipitate the exosome which was lysed directly with Qiazol reagent (miRNAasy Mini Kit, Qiagen) for microRNA extraction.

Intestinal tissues were detached (~5 cm), cut into small pieces and enzymatically digested for 2 h with 1 mg/ml type II collagenase (STEMCELL technology, Cat# 07418) as described before.30 The tissue fragments were centrifuged at 300 × g for 10 min, after which the supernatant was collected and filtered through the 0.22 µm filter. Exosome was isolated from the filtered solution using the ExoQuick isolation kit (System Biosciences, Palo Alto, CA, US) according to the manufacturer’s protocol. Exosome was then lysed directly with Qiazol reagent (miRNAasy Mini Kit, Qiagen) for microRNA extraction.

Western blot
Total proteins (20 µg) were extracted from intestinal organoids or EV pellets lysed with radio-immunoprecipitation assay buffer (Thermo Fisher Scientific, Waltham, MA, US) plus fresh protease and phosphatase inhibitors (Roche, Indianapolis, IN, US), then loaded to each lane and separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis, and then transferred to a 0.45 µm pore size nitrocellulose membrane (Bio-Rad, Hercules, CA, US). The antibodies used in western blot assay were shown in Supplementary Table 1.

Immunocytochemistry
To determine whether recipient cells have the ability to take up EVs, a lipid-associating fluorescent dye (PKH67; Sigma-Aldrich, St. Louis, MO, US) was used to label EVs as previously described. BMDCs were grown in the Nunc™ Lab-Tek™ II Chamber Slide™ (Thermo Fisher Scientific, Waltham, MA, US). Fluorescent-labeled EVs or PBS-PKH67 controls were washed by PBS and IMDM medium, then incubated with cells for 24 h. On the next day, cells were washed twice with PBS, fixed with 4% paraformaldehyde, and were stained with F-actin antibody (Thermo Fisher Scientific, Waltham, MA, US) for 60 min. Sample slides were washed with PBS and mounted with DAPI anti-fade reagent. Images were obtained using a Leica Microscope.

Histological evaluation
Hematoxylin and eosin (H&E) staining was performed by Pathology Research Resources Laboratory at University of Miami. The pathological score was evaluated using histological scoring system as previously described.31

Quantitative real-time PCR
Total RNAs were isolated from EVs or organoids with TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, US). The levels of multiple cytokines were detected by quantitative real-time PCR using the High Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific, Waltham, MA, US) and the LightCycler® 480 System (Roche, Indianapolis, IN, US). Primers used for Quantitative rt-PCR were shown in Supplementary Table 2.

MicroRNA PCR arrays
The detection and quantification of microRNA from cells, EVs, or organoids were performed with miScript PCR System (Qiagen, Hilden, Germany). Briefly, cDNA is prepared using the miScript II RT Kit with total RNA isolated from cells, EVs or organoids and is used as template in real-time PCR with the miScript miRNA PCR Array and SYBR Green PCR Kit. Data analysis is based on the ΔΔCT method with normalization of the raw data to the housekeeping genes including: SNORD61, SNORD68, SNORD72, SNORD95, SNORD96A and RNU6-6P.

The miScript Primer Assays of designed primers combined with an endogenous reference RNA (U6) were used to evaluate the variability of expression level of target microRNAs in EVs derived from saline or morphine-treated organoids.

Transfection of LNA microRNA inhibitor
LNA-enhanced antisense microRNA NC inhibitor or Let7c-5p inhibitor (Qiagen) was added directly into the culture medium of BMDC at the concentration of 100 nM. 72 h later, the cells were collected to check the Let7c-5p level or treated with organoid-derived EVs and LPS.

Enzyme-linked immunosorbent assay (ELISA)
EVs were added to recipient cells, cultured in Bovine Exosome-free medium in 6-well plates for 24 h. Conditioned medium was collected and centrifuged (3000 × g) to clear the supernatants, which were subsequently used for cytokine detection by ELISA. For in vivo experiments, serum and spleen from mice were processed for cytokine detection. Cytokines in the cell culture supernatant or animal organs were detected by TNF-α and IL-6 ELISA kits (Invitrogen Life Technologies, Carlsbad, CA, US) according to the manufacturer’s protocols. The Cytokine concentrations were determined by absorbance in triplicates with a Spectra Max M5 plate reader, running Softmax Pro 5 software.

Statistics
Data were presented as mean ± SEM. Statistical analysis was performed with GraphPad Prism 6.0 (GraphPad Software, San Diego, CA) software. Unpaired Student t test or one-way analysis of variance was adopted for analysis. Significance levels were denoted as *p < 0.05, **p < 0.01, or ***p < 0.001.

ACKNOWLEDGEMENTS
This work received support from the National Institutes of Health grants R01 DA050542, R01 DA043252, R01 DA037843, R01 DA044582, R01 DA047089, and R01 DA050542 and Florida state grant, William G. “Bill” Bankhead, Jr., and David Coley Cancer Research Program 20812 to S.R., and from the Miami Center for AIDS research (CFAR) at the University of Miami Miller School of Medicine funded by a grant P30AI073961 from the National Institutes of Health (NIH) to J.M. We thank Dr. Maria Abreu for providing us L-WRN cell line and human organoid culture.

AUTHOR CONTRIBUTIONS
S.R., Y.Z., Y.Y., and J.M. provided substantial contributions to the conception of the work. Y.Z., Y.Y., and J.M. initiated the study design and contribute equally in the execution, analysis or interpretation of data. M.G. and S.R. helped with the implementation of the study. All authors substantially contributed to the drafting, reviewing, and critically reviewing the paper for important intellectual content.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41385-021-00392-9.

Competing interests: The authors declare no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
REFERENCES

1. Valadi, H. et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9, 654–659 (2007).

2. Théry, C. et al. Indirect activation of naïve CD4 + T cells by dendritic cell-derived exosomes. Nat. Immunol. 3, 1156–1162 (2002).

3. Li, T.-L. et al. Intestinal epithelial cell-derived integrin α6β1 plays an important role in the induction of regulatory T cells and inhibits an antigen-specific Th2 response. J. Leukoc. Biol. 90, 751–759 (2011).

4. Valenti, R. et al. Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res. 67, 2912–2915 (2007).

5. Bretz, N. P. et al. Body fluid exosomes promote secretion of inflammatory cytokines in monocytic cells via Toll-Like receptor signaling. J. Biol. Chem. 288, 36691–36702 (2013).

6. Banerjee, S. et al. Morphine induced exacerbation of sepsis is mediated by tempering endotoxin tolerance through modulation of miR-146a. Sci. Rep. 1, 1–12 (2013).

7. Meng, J. et al. Opioid exacerbation of gram-positive sepsis, induced by gut microbial modulation, is rescued by IL-17A neutralization. Sci. Rep. 5, 10918 (2015).

8. Théry, C., Clayton A., Amigorena, S. & Raposo, G. Isolation and characterization of exosomes from cell culture supernatants. Curr. Protoc. Cell Biol. 30, 3.22.1–3.22.29 (2006).

9. Baer, C. et al. Endogenous RNAs modulate MicroRNA sorting to exosomes and transfer to acceptor cells. Cell Rep. 8, 1432–1446 (2014).

10. Alexander, M. et al. Exosome-delivered miRNAs modulate the inflammatory response to endotoxin. Nat. Commun. 6, 7321 (2015).

11. Mittelbrunn M. et al. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat. Commun. 2, https://doi.org/10.1038/ncomms1285 (2011).

12. Xu, A. T., Lu, J. T., Ran, Z. H. & Zheng, Q. Exosome in intestinal mucosal immunity. J. Gastroenterol. Hepatol. 31, 1694–1699 (2016).

13. Iliopoulos, D., Hirsch, H. A. & Struhl, K. An epigenetic switch involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 139, 693–706 (2009).

14. Sung, S. Y. et al. Loss of let-7 microRNA upregulates IL-6 in bone marrow-derived mesenchymal stem cells triggering a reactive stromal response to prostate cancer. PLoS ONE 8, https://doi.org/10.1371/journal.pone.0071637 (2013).

15. Sharma, U. et al. Prescription opioids induce gut dysbiosis and exacerbate colitis in a Murine model of inflammatory bowel disease. J. Crohn’s Colitis. 1–17. https://doi.org/10.1093/ecco-jcc/jjz188 (2019).

16. Targownik, L. E., Nugent, Z., Singh, H., Bugden, S. & Bernstein, C. N. The prevalence and predictors of opioid use in inflammatory bowel disease: a population-based analysis. Am. J. Gastroenterol. 109, 1613–1620 (2014).

17. Devlin, J. W. & Roberts, R. J. Pharmacology of commonly used analgesics and sedatives in the ICU: benzodiazepines, propofol, and opioids. Crit. Care Clin. 25, 431–449 (2009).

18. Burr, N. E., Smith, C., West, R., Hull, M. A. & Subramanian, V. Increasing prescription of opiates and mortality in patients with inflammatory bowel diseases in England. Clin. Gastroenterol. Hepatol. 16, 534–541 (2018), e6.

19. Cross, R. K., Wilson, K. T. & Binion, D. G. Narcotic use in patients with Crohn’s disease. Am. J. Gastroenterol. 100, 2225–2229 (2005).

20. Zhang, R. et al. Prescription opioids are associated with higher mortality in patients diagnosed with sepsis: a retrospective cohort study using electronic health records. PLoS ONE 13, e0190362 (2018).

21. Ma, Z. J. et al. Immunosuppressive effect of exosomes from mesenchymal stromal cells in defined medium on experimental colitis. Int. J. Stem Cells 12, 440–448 (2019).

22. Wang, Y. et al. Exosomes released by granulocytic myeloid-derived suppressor cells attenuate DSS-induced colitis in mice. Oncotarget 7, 15356–15368 (2016).

23. Raposo, G. & Stoorvogel, W. Extracellular vesicles: Exosomes, microvesicles, and friends. J. Cell Biol. 200, 373–383 (2013).

24. Corrado, C. et al. Exosomes as intercellular signaling organelles involved in health and disease: Basic science and clinical applications. Int. J. Mol. Sci. 14, 5338–5366 (2013).

25. Que, R., Ding, G., Chen, J. & Cao, L. Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinoma. World J. Surg. Oncol. 11, 1 (2013).

26. Hornick, N. I. et al. Serum exosome MicroRNA as a minimally-invasive early biomarker of AML. Sci. Rep. 5, 1–12 (2015).

27. Yin, X. et al. Niche-independent high-purity cultures of Lgr5+ intestinal stem cells and their progeny. Nat. Methods 11, 106–112 (2014).

28. Sato, T. et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology 141, 1762–1772 (2011).

29. Miyoshi, H. & Stappenbeck, T. S. In vitro expansion and genetic modification of gastrointestinal stem cells in spheroid culture. Nat. Protoc. 8, 2471–2482 (2013).

30. Jiang, L. et al. EpCAM-dependent extracellular vesicles from intestinal epithelial cells maintain intestinal tract immune balance. Nat. Commun. 7, 1–15 (2016).

31. Engel, M. A. et al. Ulcerative colitis in AKR mice is attenuated by intraperitoneally administered anandamide. J. Physiol. Pharmacol. 59, 673–689 (2008).